p53 immunotherapy (vaccine)
INGN 225 uses the p53 tumor suppressor in a different manner than ADVEXIN® to create a molecular immunotherapy for cancer that stimulates a particular type of immune system cell known as a dendritic cell. Testing has shown that the human immune system can recognize and kill tumors after treatment with dendritic cells stimulated by the p53 tumor suppressor, which suggests this therapy could have broad utility as a treatment for solid tumors. INGN 225 may also sensitize tumors to the effects of platinum and taxane chemotherapies.
| Cancer Indication | Status |
| Breast |  |
| Small Cell Lung | |
** We hold the worldwide commercial rights to the product candidates related to each of these programs.
